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Abstract
Purpose: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved
for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is
currently unknown to what extend this assay detects most PIK3CA mutations in BC. This information is critical as
patients and clinicians are using this and other genomic assays to indicate alpelisib.
Methods: Data from 6338 patients with BC was explored across 10 publicly available studies. The primary objective
was to evaluate the proportion and distribution of PIK3CA mutations in BC. Secondary objectives were (1) to
evaluate in silico the spectrum of PIK3CA mutations in BC that would be captured by the therascreen panel; (2) to
evaluate the proportion and distribution of PIK3CA mutations in hormone receptor-positive/HER2-negative (HR+/
HER2−), HER2+, and triple-negative BC (TNBC); and (3) to explore the identification of PIK3CA mutations in a cohort
of 48 HR+/HER2− advanced BC patients by the Guardant B360 circulating tumor DNA (ctDNA) assay.
Results: Patients with PIK3CAmut tumors represented 35.7% (2261/6338). Five PIK3CA mutations comprised 73% of
all PIK3CA mutations: H1047R (35%), E545K (17%), E542K (11%), N345K (6%), and H1047L (4%). Therascreen gene list
would capture 72% of all PIK3CA mutations and 80% of patients with a known PIK3CAmut BC. Among patients with
double PIK3CAmut tumors (12% of all PIK3CAmut), the therascreen panel would capture 78% as harboring 1 single
PIK3CA mutation, 17% as PIK3CAmut undetected, and 5% as PIK3CA double-mut. PIK3CA mutation rates were lower
in TNBC (16%) compared to HR+/HER2 (42%) and HER2+ (31%) BC; however, the distribution of the 4 main PIK3CA
mutations across subtypes was similar. Finally, 28% of PIK3CA mutations identified in ctDNA in 48 patients with
advanced HR+/HER2− BC were not part of the therascreen panel.
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Conclusion: PIK3CA mutations in BC are heterogenous and ~ 20% of patients with a known PIK3CA mutation, and
95% with a known double PIK3CAmut tumor, would not be captured by the therascreen panel. Finally, the clinical
utility of PIK3CA mutations not present in the therascreen companion diagnostic assay or identified by other
sequencing-based assays needs further investigation.
Keywords: Breast cancer, PIK3CA, Mutations, Alpelisib, Companion diagnostic, Hotspot mutations, Therascreen,
ctDNA
Introduction
Activating mutations in the PIK3CA are found in ap-
proximately 30–40% of patients with cancer and induce
hyperactivation of the alpha isoform (p110α) of the
phosphatidylinositol 3-kinase (PI3K) [1–3]. In patients
with HR+/HER2− BC, mTOR/mTOR pathway has been
associated with endocrine therapy resistance [4]. In
addition, the role of this pathway is becoming increas-
ingly important in HER2+ and TNBC [5–7]. Thus, in-
hibition of PI3K in PIK3CA-mutated BC has been a
major focus in the last decade [3].
Alpelisib is an orally bioavailable, small-molecule, α-
specific PI3K inhibitor that inhibits p110α approximately
50 times as strongly as other isoforms [8]. Following
successful preclinical and phase 1 data [4, 9], the
SOLAR-1 phase III randomized trial evaluated the effi-
cacy of alpelisib plus fulvestrant in 572 patients with
HR+/HER2− advanced BC who had received prior endo-
crine therapy [10]. A clinically relevant treatment benefit
was only observed in the cohort of patients with PIK3-
CAmut disease. In May 2019, the FDA approved alpeli-
sib for the treatment of patients with advanced
PIK3CAmut HR+/HER2− BC.
Together with alpelisib, the FDA also approved the
companion diagnostic therascreen® PIK3CA test (QIA-
GEN Manchester, Ltd.) used in SOLAR-1 to select pa-
tients who had PIK3CA mutations in tumor tissue
specimens and/or in circulating tumor DNA (ctDNA)
isolated from plasma specimens [11]. Therascreen
PIK3CA detects 11 PIK3CA hotspot mutations, mostly
found in exons 9 and 20 [11]. In SOLAR-1, the type of
PIK3CA mutation did not seem to impact the main re-
sults [10].
In this context, patients and physicians might choose
not to use the therascreen PIK3CA test and use other
available tests, which provide a more comprehensive
mutational analysis of PIK3CA as well as other genes.
This might lead to the clinical situation where PIK3CA
mutations not detected by the therascreen PIK3CA
assay, and thus not evaluated in SOLAR-1, are used to
indicate alpelisib. To define the potential frequency of
this clinical situation, here we aimed to evaluate the dis-




All non-overlapping publicly available breast datasets
(i.e., 12 studies and 6477 samples) (https://www.mbcpro-
ject.org/data-release [1, 12–21]) with PIK3CA mutational
status were interrogated from cBio Cancer Genomics
Portal (http://cbioportal.org) [22] (Fig. 1 and Add-
itional file 1). Among them, 2 studies focused on 117
patient-derived xenografts [16] and 22 fibroepithelial le-
sions of the breast [17] were removed. The remaining
combined dataset included 6338 invasive tumor samples
of which 5535 (87.3%) originated from the METABRIC
(n = 2509), the Memorial Sloan-Kettering (n = 1918), and
The Cancer Genome Atlas (n = 1108) datasets. All stud-
ies analyzed performed targeted or whole exome sequen-
cing (Table A1 Additional file 1). Only single nucleotide
variants, insertions, or short deletions in PIK3CA were
analyzed.
Therascreen PIK3CA mutation assay
The therascreen® PIK3CA RGQ PCR Kit is a real-time
qualitative PCR test for the detection of 11 mutations in
PIK3CA gene (exon 7: C420R; exon 9: E542K, E545A,
E545D, E545G, E545K, Q546E, and Q546R; and exon
20: H1047L, H1047R, and H1047Y) using genomic DNA
extracted from formalin-fixed, paraffin-embedded breast
tumor tissue or ctDNA from plasma derived from
K2EDTA anticoagulated peripheral whole blood taken
from patients with BC [11].
Immunohistochemistry (IHC)-based subtypes
IHC data was available from 5813 patients (92%). Tu-
mors were classified into the 3 main clinically relevant
subtypes: (1) HR+/HER2−, (2) HER2+, and (3) TNBC.
Tumors identified as progesterone receptor positive and
HER2− were considered HR+ regardless of estrogen re-
ceptor (ER) status. Tumors identified as ER-negative and
HER2− were considered TNBC when progesterone re-
ceptor status was not available.
Distribution of PIK3CA mutations in plasma
Frozen plasma samples from 48 patients with advanced
HR+/HER2− BC were obtained before initiating a CDK4/
6 inhibitor and endocrine therapy. Plasma samples were
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sent to Guardant Health (California, USA), and the 74-
gene standardized NGS-based assay, which includes all 21
exons from the PIK3CA gene, was performed.
Study end points
Primary objective was to evaluate the proportion and
distribution of PIK3CA mutations in BC. Secondary ob-
jectives were (1) to evaluate in silico the spectrum of
PIK3CA mutations in BC that would be captured by the
therascreen panel; (2) to evaluate the proportion and
distribution of PIK3CA mutations in HR+/HER2−,
HER2+, and TNBC; and (3) to explore the identification
of PIK3CA mutations in HR+/HER2− advanced BC by
the Guardant B360 ctDNA assay.
Statistical analyses
Patient and tumor characteristics were analyzed using
descriptive statistics.
Fig. 2 Proportion of PIK3CA mutations in BC in relation to the mutations detected by therascreen. a Proportion of patients with PIK3CA mutations
in the combined dataset. b Distribution of the various types of PIK3CA mutations in the combined dataset. c Proportion of PIK3CA mutations
detected by the therascreen assay. d Distribution of the various types of PIK3CA mutations detected by the therascreen assay in the
combined dataset
Fig. 1 The CONSORT diagram
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Results
Distribution of PIK3CA mutations in BC
In the combined dataset, 36% of patients had PIK3-
CAmut tumors (Fig. 2a). From a total of 2560
PIK3CA mutations, 205 PIK3CA mutations were
unique. The most frequent PIK3CA mutations (i.e.,
frequency ≥ 4% of all PIK3CAmut tumors) were found
in exons 4, 9, and 20: H1047R (35%), E545K (17%),
E542K (11%), N345K (6%), and H1047L (4%) (Table 1,
Fig. 2b). These 5 mutations comprised 73% of all
PIK3CA mutations identified in the combined
dataset.









Number of mutations found
in the combined dataset
Mutation
frequency (%)
H1047R 20 Yes 1 Yes 895 35.0
E545K 9 Yes 1 Yes 447 17.5
E542K 9 Yes 1 Yes 274 10.7
N345K 4 Yes Yes (preclinical only) No 142 5.5
H1047L 20 Yes 1 Yes 103 4.0
E726K 13 Inconclusive.
Probably oncogenic
Unknown No 65 2.5
C420R 7 Yes 1 Yes 48 1.9
Q546R 9 Yes 1 Yes 27 1.1
G118D 1 Yes Unknown No 26 1.0
E453K 7 Yes Unknown No 22 0.9
Q546K 1 Yes Yes (preclinical only) No 21 0.8
G1049R 20 Yes Yes (preclinical only) No 19 0.7
M1043I 20 Yes Unknown No 19 0.7
K111E 1 Yes Unknown No 16 0.6
E81K 1 Inconclusive.
Probably oncogenic
Unknown No 15 0.6
E545A 9 Yes 1 Yes 13 0.5
E545G 9 Yes 1 Yes 13 0.5
N1044K 20 Yes Unknown No 12 0.5
E110del 1 Yes Unknown No 11 0.4
Q546P 9 Yes Unknown No 10 0.4
Fig. 3 Proportion of the 18 most frequent PIK3CA mutations in PIK3CAmut BC in the combined dataset
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PIK3CA mutations captured by the therascreen panel
In the combined dataset, the proportion of PIK3CA muta-
tions included in the therascreen panel was 72% (Fig. 2c).
The most frequent types of PIK3CA mutation (i.e., fre-
quency ≥ 4% of all PIK3CAmut tumors) included in the
therascreen panel were H1047R (35%), E545K (17%),
E542K (11%), and H1047L (4%) (Fig. 2d). These 4 muta-
tions comprised 67% of all PIK3CA mutations detected in
the dataset. Of note, N345K mutation in exon 4, which
represents 6% of all tumor samples with a PIK3CA muta-
tion, is not part of the therascreen panel (Fig. 3). Although
the clinical utility of non-therascreen-detected PIK3CA
mutations is currently unknown, the N345K lies within
the C2 PI3K-type domain of the protein and confers a
gain of function on PI3K, as does C420R (a tested muta-
tion by therascreen assay) [23]. Moreover, N345K muta-
tion has shown increased sensitivity to PI3K pathway
inhibition in preclinical models [24]. Interestingly, Q546E
PIK3CA mutation included in the therascreen panel was
not found in the combined dataset.
Detection of multiple PIK3CA mutations in a tumor
sample
Among 2261 patients with PIK3CAmut tumors, 1979
(87.5%) had 1 single mutation, 267 (11.8%) had 2 muta-
tions, and 15 (0.7%) had 3 or more mutations. Overall,
patients with tumors harboring double PIK3CA muta-
tions represented 4% of all BC (Fig. 4a). Among patients
with 1 single PIK3CA mutation, 80% would have muta-
tions represented in the therascreen mutational panel
(Fig. 4b). Among patients with 2 or more PIK3CA muta-
tions, 78% would have 1 mutation represented in the
therascreen panel; 17%, no mutation represented in the
therascreen panel; and 5%, 2 or more mutations repre-
sented in the therascreen panel (Fig. 4c).
PIK3CA mutational distribution according to subtypes in
the BC dataset
Among 5813 patients with IHC data, 4055 (70%) had
HR+/HER2− disease, 995 had TNBC (17%), and 763
(13%) had HER2+ disease. PIK3CA mutations were less
frequent in TNBC (16%) than in HR+/HER2− (42%) or
HER2+ disease (31%) (Fig. 5a–c). However, the distribu-
tion of PIK3CA mutations was similar across subtypes
(Fig. 5d–f). Seventy-one percent of mutations in HR+/
HER2− BC, 75% in HER2+ BC, and 72% in TNBC would
be represented in the therascreen panel.
Distribution of PIK3CA mutations in plasma ctDNA
Therascreen assay is approved for detecting PIK3CA
mutations in ctDNA from plasma samples [25]. To
evaluate the distribution of PIK3CA mutations in ctDNA
using a highly sensitive assay that sequences all 21
PIK3CA exons, we tested plasma samples from 48 con-
secutive patients with metastatic HR+/HER2− BC from
the Hospital Clinic of Barcelona using the Guardant
B360 standardized assay [26]. All patients had recurred
or progressed to prior lines and were about to initiate a
CDK4/6 inhibitor and endocrine therapy. A PIK3CA
mutation was detected in 17 patients (37%), and 1 pa-
tient (6%) had double PIK3CA mutation. The spectrum
of PIK3CA mutations was similar to the one found in
the previous in silico population analysis (Table A2
Additional file 1). More importantly, 5 patients (28%)
had PIK3CA mutations not represented in the therasc-
reen mutational panel.
Discussion
PIK3CA mutations have recently reached level 1 evi-
dence for predicting benefit from alpelisib, an alpha-
specific PI3K inhibitor, in combination with fulvestrant
in patients with advanced HR+/HER2− BC previously
treated with endocrine therapy [10]. In addition, several
trials are now evaluating alpelisib and other alpha-
specific PI3K inhibitors in other BC subtypes harboring
PIK3CA mutations [27]. Thus, there is a need to better
understand the heterogeneity of the mutational land-
scape of PIK3CA and, at the same time, relate this het-
erogeneity with the recently introduced therascreen
Fig. 4 Proportion of patients with PIK3CA mutations in BC in relation to the mutations detected by therascreen. a Proportion of patients with
one, two, or three or more PIK3CA mutations in BC in the combined dataset. b Proportion of patients with a single PIK3CA mutation detected
PIK3CAmut by the therascreen assay. c Proportion of patients with two or more PIK3CA mutations detected by the therascreen assay as either
PIK3CA mutation “not detected,” single PIK3CA mutation or as harboring 2 or more PIK3CA mutations
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PIK3CA companion diagnostic assay approved to indi-
cate alpelisib.
To address this topic, we performed a comprehensive
evaluation of the distribution of PIK3CA mutations in
BC and made the following observations. First, although
PIK3CA mutations are highly heterogeneous, 5 muta-
tions (H1047R, E545K, E542K, N345K, and H1047L)
represented ~ 70% of all known types of PIK3CA muta-
tions in the dataset. Second, the therascreen PIK3CA
mutational panel would represent 72% of all the known
PIK3CA mutations and 80% of all patients with a known
PIK3CA mutation. Third, 83% of patients with 2 or
more PIK3CA known mutations would have muta-
tions found in the therascreen panel; however, in 78%
of the cases, only 1 single PIK3CA mutation would be
represented in the therascreen assay. Finally, the pro-
portion of PIK3CA mutations differed by BC subtype
with HR+/HER2− disease having the highest propor-
tion, followed by HER2+ disease and TNBC. Although
less frequent in the HER2+ and TNBC, the propor-
tion is not negligible and several studies, including
pivotal or registrational clinical trials, are focusing on
these two populations [5–7]. To our knowledge, this
is the first report to perform a comprehensive analysis
of PIK3CA mutations in BC and to relate these find-
ings with the type of mutations captured by the ther-
ascreen PIK3CA assay across the three main subtypes
of BC.
The SOLAR-1 phase III trial that led to the approval
of alpelisib used the therascreen PIK3CA 11-mutation
assay in tumor tissue to identify PIK3CA mutations [10].
From a total of 1173 patients tested for PIK3CA muta-
tion status that had interpretable results, 341 (29%) pa-
tients had PIK3CAmut disease [10], a proportion which
is very similar (28%) to our predicted results if the assay
would have been performed in our combined dataset.
More importantly, mutations in exon 9 versus exon 20
predicted similarly the degree of benefit to alpelisib in
SOLAR-1 [10]. Thus, based on these results, the FDA
approved the use of this assay in tumor and plasma sam-
ples as a companion diagnostic to indicate alpelisib. The
approval of therascreen in plasma samples is based on a
subanalysis of the SOLAR-1 trial which showed that
PIK3CA mutations identified in plasma samples were
also associated with treatment benefit [28].
Our results have important considerations for patients
and physicians. In certain parts of the world, determin-
ation of PIK3CA status is commonplace using various
types of sequencing-based assays. Some of these widely
used assays such as Foundation One CDx or Guard-
ant360 cover most or all exons of the PIK3CA gene.
Thus, it is highly likely that mutations which are not
part of the therascreen PIK3CA 11-mutation assay will
be identified with other assays and treatment decisions
will be made. In other parts of the world that have not
yet implemented somatic genetic testing in BC, the fact
Fig. 5 Proportion of PIK3CA mutations across the BC subtypes. a Proportion of PIK3CA mutations in HR+/HER2-negative BC. b Proportion of
PIK3CA mutations in HER2+ BC. c Proportion of PIK3CA mutations in TNBC. d Distribution of the various types of PIK3CA mutations in PIK3CAmut
HR+/HER2-negative BC. e Distribution of the various types of PIK3CA mutations in PIK3CAmut HER2+ BC. f Distribution of the various types of
PIK3CA mutations in PIK3CAmut TNBC
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that the therascreen panel misses ~ 20–30% of patients
with known PIK3CA mutations might be a reason to
choose more comprehensive PIK3CA panels.
Critical questions raised by our results are if patients
with PIK3CA mutations which are not part of the ther-
ascreen panel, or hotspot and non-hotspot PIK3CA mu-
tations identified using sequencing-based assays with
higher sensitivities than therascreen, will benefit from
alpelisib. For example, mutation N345K represented
5.5% of all PIK3CA mutations in the analyzed dataset
and is not captured by the therascreen assay. This muta-
tion was the fourth most frequent PIK3CA mutation in
the BC dataset, and COSMIC [29] and OncoKB [30]
datasets consider it pathogenic (score 0.95) and onco-
genic. Moreover, N345K confers a gain of function and
it has shown to increase sensitivity to PI3K inhibitors in
preclinical models [23, 24]. A similar situation exists for
the sixth most frequently observed PIK3CA mutation,
E726K, although OncoKB [30] states that there is con-
flicting and/or weak data describing the oncogenic func-
tion of this mutation, it has been shown that as a single
mutation it is weakly activating but as a double mutation
(with E545K or H1047R) it is synergistically activating
[31]. It is important to notice that the vast majority of
E726K mutations are found precisely as double mutants
in BC [31]. On the other hand, some less frequent muta-
tions, as G1049R, have demonstrated strong driver activ-
ity in a mutation assessment platform. G1049R exhibited
activity levels similar to the E542K variant with 20-fold
higher frequency [24]. Thus, better functional
characterization of these and other non-hotspot PIK3CA
mutations together with clinical evidence that predict
benefit to alpelisib and other alpha-specific PI3K inhibi-
tors is now of uttermost importance. At the end of the
day, each type of PIK3CA mutation should be consid-
ered a biomarker by itself.
Another interesting observation is that ~ 4% of all BC,
or ~ 12% of all patients with PIK3CAmut BC, have
double PIK3CA mutations. Preclinically, double com-
pound PIK3CA mutations result in increased PI3K activ-
ity and downstream signaling compared to single
hotspot mutants in nontransformed cells and in HR+
BC cells [31]. More importantly, these compound muta-
tions seem to predict for increased sensitivity to PI3K
alpha-specific inhibitors compared to single hotspot mu-
tants in both preclinical models and also in selected pa-
tients with BC treated in early phase 1 trials [31].
According to our results, the therascreen panel would
not capture well double PIK3CA mutations since only
5% of patients known to harbor 2 or more PIK3CA mu-
tations would have mutations represented in the therasc-
reen panel. Thus, if double mutations are confirmed to
be a biomarker of ultra-high sensitivity to alpelisib, the
therascreen assay might not be ideal for this purpose.
Our study has limitations worth noting. First, we did
not evaluate the actual analytical concordance of the
therascreen assay versus other sequencing assays. In
other words, we assumed that the results of the com-
bined dataset using various sequencing-based strategies
was the gold standard and that the therascreen assay
would identify 100% of all the PIK3CA-wild-type tumors
as “no PIK3CA mutation detected” and 100% of all the
PIK3CAmut tumors in the combined dataset as “PIK3-
CAmut” if the type of mutation was on the therascreen
mutation panel. However, the differences in the sensitive
and specificity of the various sequencing assays will
affect the concordance rates among them [32, 33]. Ac-
cording to the FDA therascreen PIK3CA assay specifica-
tion sheet, the overall percent agreement between the
therascreen assay and an NGS-based assay in SOLAR-1
was 94.7%. Second, the next-generation sequencing as-
says and the methods used across the 10 studies evalu-
ated in our study are highly heterogeneous and most are
not standardized. Third, the analyzed datasets were
mostly from primary tumor samples and acquisition of
new PIK3CA mutations has been described in the meta-
static setting in 8–10% of the cases [34]. Whether the
frequency and spectrum of PIK3CA mutations would
change if metastatic-only samples had been analyzed is
currently unknown.
Conclusion
PIK3CA somatic mutations in BC are highly
heterogenous, and the currently validated therascreen
companion diagnostic test, which covers 11 hotspot mu-
tations, might not capture up to 20% of patients with
PIK3CA mutations. Thus, there is an urgent need to bet-
ter understand if patients with PIK3CA mutations not
detected by the therascreen assay, and predicted to be
oncogenic and activating, can benefit from alpelisib or
other PI3K inhibitors. Better functional characterization
of these and other non-hotspot PIK3CA mutations to-
gether with further clinical studies in tumor and plasma
samples from SOLAR-1 and other studies will help to
better determine the population of patients who benefit
from alpelisib or other alpha-specific PI3K inhibitors.
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